

Contents

	<i>Page</i>
SUMMARY	1
INTRODUCTION	3
DESCRIPTION OF GAUCHER DISEASE	3
Forms of the Disease	3
Prevalence	4
Diagnosis	6
Treatment	6
ENZYME REPLACEMENT THERAPY	7
Mode of Administration	7
Clinical Experience	7
Conclusions Regarding Efficacy	11
Conclusions Regarding Appropriate Dosing Regimens	12
THE DISCOVERY AND DEVELOPMENT OF ALGLUCERASE	13
History of Alglucerase Development	13
The Cost of Developing Alglucerase	16
Conclusions About the Discovery and Development of Alglucerase	17
THE COST OF MANUFACTURING, DISTRIBUTING, AND MARKETING PLACENTAL ALGLUCERASE	17
POTENTIAL ADVANCES IN THERAPY FOR GAUCHER DISEASE	18
PAYING FOR ALGLUCERASE THERAPY	19
Cost of Treatment	19
Who Pays the Cost of Alglucerase Treatment?	20
Insurance Payment for Alglucerase Therapy	21
POTENTIAL CONSEQUENCES OF FEDERAL SUBSIDIES	27
CONCLUSION	28
REFERENCES	29

Figure

<i>Figure</i>	<i>Page</i>
1. Cumulative Per Patient Insurance Costs for Alglucerase Therapy Under Four Potential Dosing Regimens	25

Tables

<i>Table</i>	<i>Page</i>
1. Incidence of Gaucher Disease in the United States	5
2. Clinical Experience With Ceredase	8
3. Clinical and Experimental Evidence Supporting Low-Dose Therapy Unfractionated	10
4. Scientific Basis for Biweekly High-Dose Unfractionated Versus Low-Dose Fractionated ..	11
5. The Development of Ceredase	13
6. NIH Contracts Pertaining to Alglucerase	15
7. Estimated Annual Per Patient Drug and Ancillary Charges for Alglucerase Therapy Under Four Potential Dosing Regimens	20
8. Distribution of Alglucerase Patients by Primary Payer	21
9. Selected Insurance Characteristics of Full-Time Participants in Employment-Based Plans at Medium and Large Firms	23